See more : Electro Aço Altona S.A. (EALT4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Rad Laboratories, Inc. (BIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Rad Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Molson Coors Beverage Company (TAP-A) Income Statement Analysis – Financial Results
- Ingress Industrial (Thailand) Public Company Limited (INGRS.BK) Income Statement Analysis – Financial Results
- Alchemy Creative, Inc. (ALMY) Income Statement Analysis – Financial Results
- NET263 Ltd. (002467.SZ) Income Statement Analysis – Financial Results
- SÜSS MicroTec SE (SMHN.DE) Income Statement Analysis – Financial Results
Bio-Rad Laboratories, Inc. (BIO)
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B | 2.13B | 2.07B | 2.07B | 1.93B | 1.78B | 1.76B | 1.46B | 1.27B | 1.18B | 1.09B | 1.00B | 892.72M | 817.51M | 725.88M | 549.50M | 441.90M | 426.90M | 418.80M | 396.60M | 355.30M | 328.60M | 330.30M | 310.70M | 286.70M | 236.30M | 198.90M | 159.50M | 126.60M | 102.30M |
| Cost of Revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.75M | 930.09M | 897.77M | 996.53M | 954.22M | 908.19M | 895.64M | 835.63M | 784.40M | 801.84M | 669.69M | 561.39M | 534.50M | 479.94M | 437.99M | 383.24M | 356.33M | 300.06M | 227.70M | 181.50M | 169.90M | 164.10M | 155.20M | 139.00M | 134.40M | 124.30M | 122.20M | 113.30M | 95.30M | 81.50M | 63.50M | 52.70M | 45.60M |
| Gross Profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B | 1.12B | 1.18B | 1.18B | 1.16B | 1.18B | 1.09B | 999.84M | 962.52M | 791.36M | 712.54M | 646.49M | 610.07M | 565.39M | 509.49M | 461.18M | 425.83M | 321.80M | 260.40M | 257.00M | 254.70M | 241.40M | 216.30M | 194.20M | 206.00M | 188.50M | 173.40M | 141.00M | 117.40M | 96.00M | 73.90M | 56.70M |
| Gross Profit Ratio | 53.58% | 55.93% | 56.14% | 56.48% | 54.38% | 53.46% | 54.97% | 55.03% | 55.54% | 54.18% | 55.26% | 56.11% | 56.81% | 56.64% | 56.04% | 54.55% | 54.16% | 55.93% | 54.74% | 55.97% | 56.35% | 57.07% | 56.41% | 58.66% | 58.56% | 58.93% | 60.20% | 60.82% | 60.87% | 60.88% | 59.10% | 62.37% | 60.67% | 60.48% | 59.67% | 59.02% | 60.19% | 58.37% | 55.43% |
| Research & Development | 226.93M | 256.89M | 271.66M | 226.60M | 202.71M | 199.20M | 250.30M | 205.86M | 192.97M | 220.33M | 210.95M | 214.04M | 186.44M | 172.27M | 163.59M | 159.52M | 140.54M | 123.38M | 115.10M | 108.34M | 94.27M | 82.94M | 76.54M | 68.14M | 51.20M | 41.40M | 46.10M | 39.60M | 34.70M | 30.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 834.78M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 0.00 | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 820.62M | 827.83M | 879.57M | 800.27M | 824.63M | 833.29M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 635.21M | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Other Expenses | 0.00 | 44.57M | 26.78M | 24.49M | 26.09M | 36.59M | 12.20M | 14.85M | 11.08M | 13.01M | 12.77M | 21.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| Operating Expenses | 1.09B | 1.08B | 1.15B | 1.03B | 1.03B | 1.03B | 1.06B | 1.02B | 954.96M | 1.03B | 1.01B | 896.94M | 882.73M | 807.48M | 765.05M | 808.34M | 648.51M | 562.33M | 531.19M | 486.61M | 419.63M | 372.11M | 349.15M | 359.06M | 273.20M | 229.40M | 230.40M | 213.00M | 201.70M | 179.60M | 183.80M | 191.50M | 166.40M | 149.00M | 119.90M | 97.60M | 79.60M | 62.00M | 48.00M |
| Cost & Expenses | 2.29B | 2.32B | 2.43B | 2.13B | 2.08B | 2.10B | 2.03B | 1.95B | 1.85B | 2.03B | 1.96B | 1.81B | 1.78B | 1.64B | 1.55B | 1.61B | 1.32B | 1.12B | 1.07B | 966.55M | 857.62M | 755.35M | 705.48M | 659.12M | 500.90M | 410.90M | 400.30M | 377.10M | 356.90M | 318.60M | 318.20M | 315.80M | 288.60M | 262.30M | 215.20M | 179.10M | 143.10M | 114.70M | 93.60M |
| Interest Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M | 26.60M | 19.10M | 14.70M | 10.10M | 13.50M | 13.40M | 11.40M | 8.20M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M | 21.91M | 21.94M | 21.69M | 22.13M | 61.27M | 49.26M | 53.14M | 63.72M | 47.02M | 32.11M | 31.61M | 32.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.90M | 177.20M | 176.90M | 175.20M | 174.50M | 138.10M | 148.70M | 142.90M | 131.85M | 149.89M | 147.16M | 130.42M | 120.96M | 108.91M | 101.68M | 97.09M | 67.30M | 55.40M | 61.00M | 56.20M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| EBITDA | -608.26M | -4.49B | 5.63B | 5.10B | 2.46B | 674.72M | 269.52M | 206.40M | 299.34M | 303.59M | 305.26M | 404.44M | 409.90M | 392.90M | 334.56M | 272.06M | 219.75M | 229.40M | 176.30M | 173.75M | 189.43M | 180.14M | 153.33M | 110.08M | 76.09M | 52.12M | 46.10M | 56.90M | 56.40M | 53.50M | 27.00M | 28.40M | 34.20M | 34.70M | 29.00M | 26.20M | 21.50M | 15.20M | 10.70M |
| EBITDA Ratio | -22.77% | 23.71% | 22.24% | 22.53% | 16.87% | 16.01% | 13.38% | 13.21% | 15.33% | 14.39% | 15.44% | 20.12% | 20.07% | 20.39% | 18.86% | 13.77% | 13.73% | 14.27% | 14.02% | 17.03% | 18.82% | 20.18% | 21.56% | 13.88% | 17.54% | 10.23% | 11.43% | 14.73% | 14.65% | 16.92% | 7.36% | 1.82% | 11.26% | 12.07% | 11.89% | 12.82% | 13.35% | 12.16% | 10.07% |
| Operating Income | 365.70M | 482.62M | 489.43M | 410.96M | 229.66M | -108.64M | 116.65M | 53.19M | 166.71M | 149.98M | 169.46M | 264.11M | 295.16M | 284.01M | 230.99M | 182.94M | 135.19M | 146.11M | 115.30M | 108.85M | 145.76M | 137.38M | 112.03M | 66.77M | 48.60M | 31.00M | 26.60M | 41.70M | 39.70M | 36.70M | 10.40M | 14.50M | 22.10M | 24.40M | 21.10M | 19.80M | 16.40M | 11.90M | 8.70M |
| Operating Income Ratio | 13.69% | 17.22% | 16.75% | 16.14% | 9.93% | -4.74% | 5.40% | 2.57% | 8.26% | 6.90% | 7.95% | 12.76% | 14.23% | 14.74% | 12.95% | 10.37% | 9.25% | 11.47% | 9.76% | 9.99% | 14.53% | 15.39% | 13.70% | 9.20% | 8.84% | 7.02% | 6.23% | 9.96% | 10.01% | 10.33% | 3.16% | 4.39% | 7.11% | 8.51% | 8.93% | 9.95% | 10.28% | 9.40% | 8.50% |
| Total Other Income/Expenses | -1.22B | -5.19B | 4.95B | 4.49B | 2.03B | 319.39M | -15.35M | -73.94M | -20.86M | -18.43M | -57.07M | -34.27M | -59.39M | -63.73M | -45.16M | -40.10M | -14.35M | -4.08M | -21.93M | -11.52M | -32.07M | -32.97M | -47.06M | -21.32M | -32.18M | 3.23M | -3.80M | -2.50M | -6.10M | -12.70M | -5.70M | 13.10M | -8.50M | -7.20M | -5.30M | -4.60M | -3.70M | -2.40M | -2.70M |
| Income Before Tax | -850.10M | -4.70B | 5.44B | 4.91B | 2.26B | 507.36M | 97.81M | 41.56M | 145.85M | 131.56M | 112.39M | 231.58M | 235.76M | 220.28M | 185.83M | 142.84M | 120.84M | 142.03M | 93.37M | 97.33M | 113.69M | 104.41M | 64.97M | 45.44M | 16.40M | 34.20M | 22.80M | 36.50M | 33.60M | 24.00M | 4.70M | 27.60M | 13.60M | 17.20M | 15.80M | 15.20M | 12.70M | 9.50M | 6.00M |
| Income Before Tax Ratio | -31.82% | -167.87% | 186.08% | 192.79% | 97.81% | 22.15% | 4.53% | 2.01% | 7.22% | 6.05% | 5.27% | 11.19% | 11.37% | 11.43% | 10.42% | 8.10% | 8.27% | 11.15% | 7.91% | 8.93% | 11.33% | 11.70% | 7.95% | 6.26% | 2.98% | 7.74% | 5.34% | 8.72% | 8.47% | 6.75% | 1.43% | 8.36% | 4.38% | 6.00% | 6.69% | 7.64% | 7.96% | 7.50% | 5.87% |
| Income Tax Expense | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M | 146.36M | -16.94M | 13.44M | 32.75M | 42.71M | 34.57M | 62.28M | 57.74M | 33.35M | 36.67M | 44.58M | 26.55M | 38.76M | 15.79M | 31.04M | 37.52M | 36.54M | 20.79M | 13.63M | 4.70M | 9.90M | 6.40M | 9.10M | 8.40M | 8.40M | 1.90M | 12.00M | 5.40M | 6.50M | 5.70M | 5.70M | 5.00M | 3.40M | 1.70M |
| Net Income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.13M | 113.09M | 88.85M | 77.79M | 169.23M | 178.22M | 185.49M | 144.62M | 89.51M | 92.99M | 103.26M | 81.55M | 68.24M | 76.17M | 67.86M | 44.18M | 31.10M | 11.70M | 24.30M | 16.40M | 26.20M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M | 9.50M | 7.70M | 6.10M | 4.30M |
| Net Income Ratio | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | 15.76% | 5.31% | 1.36% | 5.60% | 4.08% | 3.65% | 8.18% | 8.60% | 9.63% | 8.11% | 5.07% | 6.36% | 8.11% | 6.91% | 6.26% | 7.59% | 7.60% | 5.40% | 4.28% | 2.13% | 5.50% | 3.84% | 6.26% | 6.35% | 4.39% | 0.85% | 4.72% | 2.64% | 3.73% | 4.27% | 4.78% | 4.83% | 4.82% | 4.20% |
| EPS | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 | 2.72 | 5.85 | 6.39 | 6.70 | 5.28 | 3.30 | 3.48 | 3.92 | 3.13 | 2.65 | 3.00 | 2.70 | 1.79 | 1.27 | 0.49 | 0.99 | 0.67 | 1.07 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| EPS Diluted | -21.82 | -121.79 | 140.83 | 126.20 | 58.27 | 11.94 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 | 3.41 | 3.83 | 3.06 | 2.58 | 2.90 | 2.61 | 1.74 | 1.27 | 0.48 | 0.99 | 0.66 | 1.05 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M | 29.19M | 28.88M | 28.59M | 28.29M | 28.03M | 27.67M | 27.40M | 27.11M | 26.72M | 26.38M | 26.06M | 25.72M | 25.42M | 25.13M | 24.65M | 24.42M | 24.22M | 24.53M | 24.66M | 24.60M | 24.41M | 24.23M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
| Weighted Avg Shares Out (Dil) | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M | 29.41M | 29.13M | 28.91M | 28.64M | 28.47M | 28.15M | 27.83M | 27.64M | 27.29M | 26.95M | 26.66M | 26.49M | 26.31M | 26.00M | 25.44M | 24.57M | 24.33M | 24.72M | 24.85M | 24.95M | 24.41M | 24.26M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
MINNEAPOLIS , Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October...
BIO-key Expands Deployment with Province of British Columbia, Adds 10,000 Biometric Users for Sign-on and Physical Access Control
BIO-key, International (BKYI) Expands Deployment with Province of British Columbia, Adds 10,000 Biometric Users for Sign-on and Physical Access Control.
BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT
MINNEAPOLIS , Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives.
BIO-key International Enters into $1.9 Million Warrant Inducement
HOLMDEL, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, today announced...
Leading Government Defense Ministry Awards BIO-key $500K In Follow-On Orders for Biometric User Authentication
HOLMDEL, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that...
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK , Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September...
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
MINNEAPOLIS , Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT...
Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in...
Identity and Access Management Software Provider BIO-key to Participate at H.C. Wainwright Investment Conf.
HOLMDEL, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, will participate at H.C.
Source: https://incomestatements.info
Category: Stock Reports